Our top pick for
IGM Biosciences, Inc is a biotechnology business based in the US. IGM Biosciences shares (IGMS) are listed on the NASDAQ and all prices are listed in US Dollars. IGM Biosciences employs 91 staff and has a market cap (total outstanding shares value) of USD$2.3 billion.
Since the stock market crash in March caused by coronavirus, IGM Biosciences's share price has had significant negative movement.
Its last market close was USD$54, which is 11.02% down on its pre-crash value of USD$60.69 and 96.01% up on the lowest point reached during the March crash when the shares fell as low as USD$27.55.
If you had bought USD$1,000 worth of IGM Biosciences shares at the start of February 2020, those shares would have been worth USD$1,327.66 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,388.34.
|Latest market close||USD$54|
|52-week range||USD$18.89 - USD$89.81|
|50-day moving average||USD$68.3203|
|200-day moving average||USD$61.3064|
|Wall St. target price||USD$82.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-71.751|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-17)||0.43%|
|1 month (2020-10-27)||-10.55%|
|3 months (2020-08-25)||18.76%|
|6 months (2020-05-23)||N/A|
|1 year (2019-11-25)||139.79%|
|2 years (2018-11-23)||N/A|
|3 years (2017-11-23)||N/A|
|5 years (2015-11-23)||N/A|
|Gross profit TTM||USD$-22,649,000|
|Return on assets TTM||-29.09%|
|Return on equity TTM||-49.4%|
|Market capitalisation||USD$2.3 billion|
TTM: trailing 12 months
There are currently 1.6 million IGM Biosciences shares held short by investors – that's known as IGM Biosciences's "short interest". This figure is 0.8% up from 1.6 million last month.
There are a few different ways that this level of interest in shorting IGM Biosciences shares can be evaluated.
IGM Biosciences's "short interest ratio" (SIR) is the quantity of IGM Biosciences shares currently shorted divided by the average quantity of IGM Biosciences shares traded daily (recently around 224939.16786227). IGM Biosciences's SIR currently stands at 6.97. In other words for every 100,000 IGM Biosciences shares traded daily on the market, roughly 6970 shares are currently held short.
However IGM Biosciences's short interest can also be evaluated against the total number of IGM Biosciences shares, or, against the total number of tradable IGM Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IGM Biosciences's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 IGM Biosciences shares in existence, roughly 50 shares are currently held short) or 0.2205% of the tradable shares (for every 100,000 tradable IGM Biosciences shares, roughly 221 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against IGM Biosciences.
Find out more about how you can short IGM Biosciences stock.
We're not expecting IGM Biosciences to pay a dividend over the next 12 months.
IGM Biosciences, Inc., a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies. It is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 proteins; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. IGM Biosciences, Inc. has a collaboration with Atreca Inc. and BeiGene Ltd. to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19; and strategic research collaboration and license agreement with AbCellera to discover and develop IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Everything we know about the Qilian International Holding Group IPO, plus information on how to buy in.
Everything we know about the AbCellera Biologics IPO, plus information on how to buy in.
Steps to owning and managing CALM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BG, with 24-hour and historical pricing before you buy.
Steps to owning and managing BCLI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLBD, with 24-hour and historical pricing before you buy.
Steps to owning and managing BDTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RILYO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASPN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.